Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Myrica is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Diabetic peripheral neuropathy (DPN) in adults: The maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Treatment should begin at 50 mg three times a day (150 mg/day). Based on how well it works and how well the patient tolerates it, the dose may be raised to 300 mg/day within 1 week. For the Pregabalin CR capsule, start at 165 mg once daily and increase to 330 mg once daily within 1 week, depending on the individual patient's response and tolerability. The maximum recommended dose of the Pregabalin CR capsule is 330 mg once daily. Postherpetic neuralgia (PHN) in adults: The recommended dose of Pregabalin is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Treatment should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be raised to 300 mg/day within 1 week, based on efficacy and tolerability. If a patient gets insufficient pain relief after 2 to 4 weeks on 300 mg/day, and is able to tolerate Pregabalin, the dose may go up to 300 mg two times a day or 200 mg three times a day (600 mg/day). For the Pregabalin CR capsule, start at 165 mg once daily and increase to 330 mg once daily within 1 week, based on individual response and tolerability. If pain relief is insufficient after 2 to 4 weeks on 330 mg once daily, and the patient tolerates the Pregabalin CR capsule, up to 660 mg once daily may be used. The adverse reactions are dose-dependent, and more patients stop treatment because of them at higher doses. So dosing above 330 mg/day should be kept only for patients who still have ongoing pain and are tolerating 330 mg daily. The maximum recommended dose of the Pregabalin CR capsule is 660 mg once daily. Management of fibromyalgia in adults: The recommended dose of Pregabalin is 300 to 450 mg/day. Treatment should begin at 75 mg two times a day (150 mg/day). Within 1 week, the dose may be increased to 150 mg two times a day (300 mg/day), based on efficacy and tolerability. If a patient doesn't get enough benefit from 300 mg/day, it may be increased further to 225 mg two times a day (450 mg/day). Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Pregabalin is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week, based on efficacy and tolerability. Patients who don't get enough pain relief after 2 to 3 weeks on 150 mg two times a day, and who tolerate Pregabalin, may be treated with up to 300 mg two times a day. Conversion from Pregabalin capsules to Pregabalin CR capsule: When switching, patients should take their morning dose of the Pregabalin capsule as prescribed on the day of the switch. They should then start the Pregabalin CR capsule after an evening meal. Pregabalin total daily dose (taken 2 or 3 times daily) and the matching Pregabalin CR capsule dose (taken once a day): 75 mg/day: 82.5 mg/day 150 mg/day: 165 mg/day 225 mg/day: 247.5 mg/day 300 mg/day: 330 mg/day 450 mg/day: 495 mg/day 600 mg/day: 660 mg/day
Side Effects
Most adults taking pregabalin tend to notice dizziness and drowsiness, along with dry mouth, swelling (edema), blurred vision, weight gain, and some difficulty concentrating or thinking clearly. In children being treated for partial-onset seizures, the main issues reported are weight gain and an increased appetite.
Cautions & Contraindications
Warnings & Precautions
Angioedema (for example, swelling of the throat, head, and neck) can occur and may be associated with life threatening respiratory compromise requiring emergency treatment. Rebalin should be discontinued immediately in these cases. Rebalin should also be discontinued immediately if hypersensitivity reactions (for example, hives, dyspnea and wheezing) occur. Antiepileptic drugs, including Rebalin, increase the risk of suicidal thoughts or behavior. Respiratory depression may occur with Rebalin when it is used together with other central nervous system (CNS) depressants or in patients with underlying respiratory impairment. Patients need to be monitored and their dosage adjusted as appropriate. Rebalin may cause dizziness and somnolence and can impair a patient's ability to drive or operate machinery. Increased seizure frequency or other adverse reactions may occur if Rebalin is stopped too quickly. Rebalin should instead be withdrawn gradually over a minimum of 1 week. Rebalin may cause peripheral edema. Caution should be exercised when Rebalin is given together with thiazolidinedione antidiabetic agents.
Contraindications
Pregabalin should not be used by patients who are known to be hypersensitive to Pregabalin or to any of the other ingredients in the formulation.